Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1, 2014
Naiyer A, Rizvi,MD

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response seen with nivolumab plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Rizvi says in this study, EGFR MT chemotherapy-naïve NSCLC patients received nivolumab 3 mg/kg IV Q2W plus erlotinib 150 mg PO daily until progression or unacceptable toxicity. The study showed that the combination was very tolerable and safe.

The data also showed a response rate of 19%, Rizvi says. The one patient enrolled in the study who was erlotinib naïve had a durable and deep response for the combination. Based on these results, Rizvi believes there is potential for the combination of checkpoint inhibitors, like nivolumab, with small molecule inhibitors in patients with EGFR mutated lung cancer.

<<<

View more from the 2014 ASCO Annual Meeting

x